Medicinal composition containing calcium channel blockers, ACE inhibitors and statins

A technology of calcium ion antagonists and compositions, applied in the field of medicine, capable of solving unsatisfactory problems

Inactive Publication Date: 2009-12-30
王丽燕
View PDF6 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the compound preparation has an obvious antihypertensive effect and reduces cardiovascular morbidity and / or mortality, it is still unsatisfactory

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing calcium channel blockers, ACE inhibitors and statins
  • Medicinal composition containing calcium channel blockers, ACE inhibitors and statins
  • Medicinal composition containing calcium channel blockers, ACE inhibitors and statins

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0089] Embodiment 1: Levoamlodipine besylate, perindopril tert-butylamine salt and atorvastatin calcium tablet

[0090] Name of raw material

Specification 1 Dosage

Specification 2 Dosage

Specification 3 Dosage

levamlodipine besylate

(calculated as levamlodipine)

1.25g

2.5g

5.0g

Perindopril tert-butylamine salt

2.0g

4.0g

8.0g

Atorvastatin Calcium

(calculated as atorvastatin)

10.0g

20.0g

80.0g

calcium carbonate

152.4g

139.1g

72.6g

pregelatinized starch

20g

20g

20g

Polysorbate 80

5g

5g

5g

Magnesium stearate

0.62g

0.62g

0.62g

Micropowder silica gel

1.25g

1.25g

1.25g

microcrystalline cellulose

37.5g

37.5g

37.5g

Carboxymethyl Starch Sodium

10g

10g

10g

Crospovidone

10g

10...

Embodiment 2

[0093] Embodiment 2: Nitrendipine, enalapril maleate and fluvastatin sodium capsules

[0094] Name of raw material

Specification 1 Dosage

Specification 2 Dosage

Specification 3 Dosage

Nitrendipine

5.0g

10.0g

20.0g

enalapril maleate

2.5g

10.0g

20.0g

Fluvastatin sodium (calculated as fluvastatin)

20.0g

40.0g

80.0g

calcium carbonate

159.3g

126.8g

66.8g

pregelatinized starch

25g

25g

25g

Polysorbate 80

5.5g

5.5g

5.5g

Magnesium stearate

0.65g

0.65g

0.65g

Micropowder silica gel

1.8g

1.8g

1.8g

Sodium dodecyl sulfate

3.5g

3.5g

3.5g

sodium starch glycolate

8g

8g

8g

Crospovidone

9g

9g

9g

gelatin

9.5g

9.5g

9.5g

purified water

Appropriate amount

Appropriate amount

Appropriate amount

[0095] Preparation:

[0096]Pass ...

Embodiment 3

[0097] Example 3: Lacidipine, Nitrendipine, Ramipril and Rosuvastatin Calcium Dispersible Tablets

[0098] Name of raw material

Specification 1 Dosage

Specification 2 Dosage

Specification 3 Dosage

Lacidipine

4.0g

6.0g

8.0g

Nitrendipine

5.0g

10.0g

20.0g

Ramipril

2.5g

5.0g

20.0g

Rosuvastatin Calcium

(Based on rosuvastatin)

5.0g

10.0g

40.0g

calcium carbonate

165.7g

150.4g

141.9g

pregelatinized starch

18g

18g

18g

Polysorbate 80

4.5g

4.5g

4.5g

Magnesium stearate

0.6g

0.6g

0.6g

Micropowder silica gel

1.5g

1.5g

1.5g

microcrystalline cellulose

35g

35g

35g

sodium starch glycolate

10g

10g

10g

Crospovidone

8g

8g

8g

95% ethanol

Appropriate amount

Appropriate amount

Appropriate amount

[0099] Preparation: ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicinal composition, which comprises calcium channel blockers (CCB) or a mixture thereof, angiotensin-converting enzyme inhibitors (ACEI) or a mixture thereof, statins or a mixture thereof and a pharmaceutically acceptable carrier, wherein the calcium channel blockers are selected from levamlodipine, amlodipine, lacidipine, nitrendipine, or a mixture thereof; the angiotensin-converting enzyme inhibitors are selected from perindopril, ramipril, fosinopril, enalapril, or a mixture thereof; and the statins are selected from atorvastatin, simvastatin, rosuvastatin, fluvastatin, or a mixture thereof. The medicinal composition is used for treating various types of hypertension, treating or preventing cardio-cerebral vascular diseases related to the hypertension, reducing the incidence and / or the mortality of the cardio-cerebral vascular diseases and improving the medication compliance of patients.

Description

technical field [0001] The invention relates to a novel pharmaceutical composition, in particular to a pharmaceutical composition containing a calcium ion antagonist or a mixture thereof, an angiotensin-converting enzyme inhibitor or a mixture thereof, and a statin or a mixture thereof, belonging to the field of medicine . Background technique [0002] Due to the development of social economy and the change of people's lifestyle, the prevalence rate of hypertension in our country shows a continuous growth trend. According to the results of the national nutrition and health status survey in 2002, the prevalence rate of hypertension among adults in my country reached 18.8%. 160 million hypertensive patients. At present, one person dies of cardiovascular and cerebrovascular diseases every 15 seconds in my country, and the total morbidity and mortality of cardiovascular and cerebrovascular diseases are close to the level of developed countries. Statistics from the Ministry of H...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61P3/06A61P3/10A61P9/10A61P9/12A61P13/12A61P27/06
Inventor 王丽燕
Owner 王丽燕
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products